相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancer
Emelie Radestad et al.
ONCOIMMUNOLOGY (2019)
Overexpression of HER2/HER3 and clinical feature of ovarian cancer
Ye Won Chung et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2019)
Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells
Hans H. Oberg et al.
FRONTIERS IN IMMUNOLOGY (2018)
Prognosis of ovarian cancer is associated with effector memory CD8(+) T cell accumulation in ascites, CXCL9 levels and activation-triggered signal transduction in T cells
Sonja Lieber et al.
ONCOIMMUNOLOGY (2018)
Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
Ruea-Yea Huang et al.
ONCOIMMUNOLOGY (2017)
Recent advances of bispecific antibodies in solid tumors
Shengnan Yu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
The making of bispecific antibodies
Ulrich Brinkmann et al.
MABS (2017)
An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors
Takahiro Ishiguro et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
The Ambiguous Role of γδ T Lymphocytes in Antitumor Immunity
Guranda Chitadze et al.
TRENDS IN IMMUNOLOGY (2017)
The Unique Molecular and Cellular Microenvironment of Ovarian Cancer
Thomas Worzfeld et al.
FRONTIERS IN ONCOLOGY (2017)
Tumor-Host Cell Interactions in Ovarian Cancer: Pathways to Therapy Failure
Elke Pogge von Strandmann et al.
TRENDS IN CANCER (2017)
Tumor microenvironment: The culprit for ovarian cancer metastasis?
Zhongyue Luo et al.
CANCER LETTERS (2016)
Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients
Hans-Heinrich Oberg et al.
PANCREATOLOGY (2016)
Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer Role for Immune Monitoring
Jashodeep Datta et al.
JAMA ONCOLOGY (2016)
The prognostic landscape of genes and infiltrating immune cells across human cancers
Andrew J. Gentles et al.
NATURE MEDICINE (2015)
Progressive loss of anti-HER2 CD4+ T-helper type 1 response in breast tumorigenesis and the potential for immune restoration
Jashodeep Datta et al.
ONCOIMMUNOLOGY (2015)
HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development
J. C. Singh et al.
BRITISH JOURNAL OF CANCER (2014)
Novel Bispecific Antibodies Increase γδ T-Cell Cytotoxicity against Pancreatic Cancer Cells
Hans-Heinrich Oberg et al.
CANCER RESEARCH (2014)
Phase II Trial of the Anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Monitoring circulating γδ T cells in cancer patients to optimize γδ T cell-based immunotherapy
Hans-Heinrich Oberg et al.
FRONTIERS IN IMMUNOLOGY (2014)
Pertuzumab: new hope for patients with HER2-positive breast cancer
M. Capelan et al.
ANNALS OF ONCOLOGY (2013)
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
Sandra M. Swain et al.
LANCET ONCOLOGY (2013)
The novel tribody [(CD20)2xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells
P. Glorius et al.
LEUKEMIA (2013)
CD1d-lipid antigen recognition by the γδ TCR
Adam P. Uldrich et al.
NATURE IMMUNOLOGY (2013)
Antitumor properties of salinomycin on cisplatin-resistant human ovarian cancer cells in vitro and in vivo: Involvement of p38 MAPK activation
Bei Zhang et al.
ONCOLOGY REPORTS (2013)
Identification of Ovarian Cancer Metastatic miRNAs
Souriya Vang et al.
PLOS ONE (2013)
Human ovarian cancer stem-like cells can be efficiently killed by γδ T lymphocytes
Dongmei Lai et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
Luca Gianni et al.
LANCET ONCOLOGY (2011)
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
N. Colombo et al.
ANNALS OF ONCOLOGY (2010)
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant
David M. Gershenson et al.
GYNECOLOGIC ONCOLOGY (2009)
Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu
Alessandro D. Santin et al.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS (2008)
HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients
Marianne Tuefferd et al.
PLOS ONE (2007)
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
Junzo Hamanishi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications
J. A. Villella et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2006)
Use of trastuzumab in the treatment of metastatic endometrial cancer
E Jewell et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2006)
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
E Sato et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells
HJ Gober et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
L Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group
MA Bookman et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
V Groh et al.
NATURE (2002)
Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human γδ T cells
E Espinosa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
分享论文
